CN102716407A - Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans - Google Patents
Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans Download PDFInfo
- Publication number
- CN102716407A CN102716407A CN2012102155898A CN201210215589A CN102716407A CN 102716407 A CN102716407 A CN 102716407A CN 2012102155898 A CN2012102155898 A CN 2012102155898A CN 201210215589 A CN201210215589 A CN 201210215589A CN 102716407 A CN102716407 A CN 102716407A
- Authority
- CN
- China
- Prior art keywords
- fructus tsaoko
- oil
- medicine
- candida albicans
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans. The invention further discloses a medicine composite with the functions of restraining or killing the candida albicans. The medicine composite enables the amomum tsao-ko oil to serve as an active ingredient, and auxiliary materials or auxiliary ingredients which are acceptable on the pharmacy are added to prepare. The amomum tsao-ko oil has the functions of restraining or killing the candida albicans, can treat candida albicans diseases, and has strong practical application value.
Description
Technical field
The present invention relates to the new purposes of Fructus Tsaoko oil, belong to pharmaceutical sanitary field.
Background technology
Candida albicans bacterium (candida Albicans) is claimed again extensively to be present in nature by Candida albicans, also is one of human body normal flora, mainly survives at ordinary times in oral cavity, skin, mucosa, digestive tract, vagina and other internal organs of human body.Whether Candida albicans is the condition pathogenic fungus, and it is pathogenic to be relative, the fall ill height that depends on body immunity and quantity, the virulence of infectious bacteria.In normal body, its quantity is few, is oval, is in commensalism with body, does not cause disease.When body under the influence of some physiology, pathological factor; When Abwehrkraft des Koepers or immunity reduced, poised state was destroyed, and the candida albicans bacterium transfers the mycelia phase to mutually by yeast; In local raised growth breeding, cause that the candidiasis of skin, mucosa even general is sick.
Candida albicans can be invaded the many positions of human body, causes the various white candidiasis, as: 1. dermatocandidiasis; (internal organs nest, groin are under the breast, around the anus and nail groove for good send out in the skinfold place; Between finger); Erubescence, humidity, shinny cover one deck white sometimes or are the shape thing that breaks, and vesicle is arranged around the pathological changes.2. candidiasis of the mucous membranes is seen at most with thrush, angular cheilitis, vaginitis, after mucomembranous surface is stamped the white film that curdled milk differs in size, divests, stays the flushing substrate, and produces crack and shallow table ulcer.3. internal organs and nervus centralis candidiasis can be sent out by place pathogenic bacteria such as mucocutaneous and caused that pneumonia, gastroenteritis, endocarditis, meningitis, encephalitis etc. are arranged, and also septicemia can take place once in a while.
The colpitis mycotica that Candida albicans causes is the most common candidiasis, shows as leucorrhoea grow in quantity, pudendum, pruritus of vagina, burning sensation, and painful urination, Chang Fahong, edema around the pudendum, epidermis changes varied; Very shallow vesicle pimple can take place, and occurs in groups; It is rotten to the corn also can to form the eczema shape, and be confined to pudendum or extend to around perineum, the anus towards periphery and strand reproduction pleat, until femoribus internus, appearance, the acute or subacute eczema of all fours; Mucosa thickens near labia and the clitoris, and the skin surface flushing that contacts with each other is rotten to the corn; Can cause small white pustule individually, ulcer, vulvodynia and regional glandular enlargement take place when serious.
The common medicine of treatment candidiasis is antibiotic and broad-spectrum antifungal chemical medicine such as fluconazol, itraconazole such as nystatin.Antibiotic and azole anti-candida medicine have characteristics such as anti-fungus spectra is wide, oral absorption is complete rapidly, blood-brain barrier permeability height, but its side effect is big, and the widely-used candidiasis that can make produces drug resistance.Chinese medicine antifungal wide material sources, toxicity is little, has broad spectrum activity and drug effect is long, in the fungal cell, produces many-sided pharmacodynamics effect.Therefore, from Chinese herbal medicine, seek very necessity of anti-candida albicans new drug.
Fructus Tsaoko is the mature fruit of Zingiberaceae Amomum plant Fructus Tsaoko Amomum tsa-ko Crevost et Lemaire, main product in Yunnan, ground such as Guangxi, Guizhou.The traditional Chinese medical science thinks that it is warm in nature, and acrid in the mouth is returned spleen, stomach warp, and dampness is arranged, and the effect of warming middle-JIAO is used for cold-damp resistance card, is applicable to that the breast abdominal distention is vexed, anorexia, or gastralgia uncomfortable in chest, and the QI rising in reverse order is felt sick, and dysphagia and regurgitation and phlegm retention are gathered etc.Fructus Tsaoko contains volatile oil and Flavonoid substances, and its volatile oil is the yellow oily transparency material, has special penetrating odor.
Fructus Tsaoko oil is widely used in food, medical industry, its have effects such as antioxidation, antimutagenic, calm, anti-hepatitis virus and antifungal (Feng Xue, etc., the progress of flavoring Fructus Tsaoko volatile oil, " Chinese flavoring agent ", 2009 years 8 phases.) in addition; Fructus Tsaoko oil also has effects such as antiinflammatory, anthelmintic, antitussive, treatment gastroenteropathy and treatment bacterial infection disease; Like number of patent application: 200410022726.1; Denomination of invention: a kind ofly contain the preparation of Fructus Tsaoko volatile oil, the patent application of Preparation method and use, disclose kernel, fruit, stem, leaf, the root of planting zingiberaceous plant Fructus Tsaoko Amomum tas-ko crevost etlemaire and extracted the medicament that Chinese medicine preparation that volatile oil makes can be used for treating gastroenteropathy; Number of patent application: 200410008132.5, denomination of invention: the patent application of smart powder of Fructus Tsaoko and preparation method thereof, the smart powder of Fructus Tsaoko that discloses the Fructus Tsaoko volatile oil preparation can be used as food flavouring flavouring agent and antiinflammatory, anthelmintic, antitussive, reduce phlegm, the medicine of cold expelling etc.Number of patent application: 201010622746.8, denomination of invention: the patent application of the purposes of Fructus Tsaoko oil in the medicine of preparation treatment bacterial infectious disease discloses Fructus Tsaoko oil and can be used for treating bacterial infection disease.
Summary of the invention
Goal of the invention of the present invention is to provide the new purposes of Fructus Tsaoko oil, promptly has the new purposes in the medicine that suppresses or kill the Candida albicans effect in preparation, and also having offered with Fructus Tsaoko oil is the pharmaceutical composition of active component.
The invention provides Fructus Tsaoko oil and have the purposes in the medicine that suppresses or kill the Candida albicans effect in preparation.
Wherein, said medicine is the medicine of treatment candidiasis.
Wherein, said medicine is to control dermatocandidiasis, candidiasis of the mucous membranes, internal organs candidiasis or the oidiomycotic medicine of nervus centralis.
Wherein, said medicine is the medicine of treatment colpitis mycotica.
Wherein, described Fructus Tsaoko oil derives from the volatile oil of the mature fruit extraction of Zingiberaceae Amomum plant Fructus Tsaoko Amomum tsa-ko Crevost et Lemaire.
Wherein, described Fructus Tsaoko oil prepares through following method: get Fructus Tsaoko, be ground into coarse powder, add the distilled water of 10 ~ 14 times of weight, soak after 1 ~ 5 hour, adopt steam distillation to extract 2 ~ 6 hours, promptly get Fructus Tsaoko oil.
The present invention also provides a kind of pharmaceutical composition that suppresses or kill the Candida albicans effect that has, and it is to be active component with Fructus Tsaoko oil, adds the medicament that acceptable accessories or complementary composition are prepared from.
Wherein, described Fructus Tsaoko oil prepares through following method: get Fructus Tsaoko, be ground into coarse powder, add the distilled water of 10 ~ 14 times of weight, soak after 1 ~ 5 hour, adopt steam distillation to extract 2 ~ 6 hours, promptly get Fructus Tsaoko oil.Wherein, described medicament is external preparation, oral formulations or ejection preparation.Preferably, said external preparation is lotion, liniment, gargarism or liniment.
Wherein, containing the oily content of Fructus Tsaoko in the described preparation is 0.1%～100%w/w.
Medicine of the present invention has good antibacterial and bacteriostasis to Candida albicans, can effectively treat the various diseases that candida albicans infection causes, especially colpitic interior curative effect is definite, has good potential applicability in clinical practice.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
Below, foregoing of the present invention is remake further detailed description through the specific embodiment of embodiment form.But should this be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following instance.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
The preparation of embodiment 1 Fructus Tsaoko oil of the present invention
Get Fructus Tsaoko, pulverized the 20-40 mesh sieve, add the distilled water of 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get Fructus Tsaoko oil of the present invention.
Fructus Tsaoko oil of the present invention also can extract according to pharmacopeia (version in 2005) appendix XD determination of volatile oil method, also can adopt prior aries such as organic solvent extraction, supercritical CO 2 extraction to extract, and perhaps obtains through the mode of buying the commercially available prod.
Below prove beneficial effect of the present invention through the test of pesticide effectiveness:
Material and instrument
1.1 experimental strain
1. type strain: Candida albicans type strain (ATCC14053), from DSMZ of U.S. clinical laboratory; Candida albicans type strain (CICC32819) and Candida albicans type strain (CICC31284) are available from Chinese industrial microorganism fungus kind preservation administrative center.
2. clinical separation strain: 14 strains are located away from the out-patient's of Sichuan Province gynecological of healthcare hospital for women & children respiratory tract, skin, vagina etc., and identify that through the KC-16 of BIO-KONT company lath and drug sensitive test paper are accredited as Candida albicans during in JIUYUE, 2011 to the December in.
1.2 medicine
Trial drug: medicine Fructus Tsaoko oil of the present invention.
Positive drug: the Mycoporin vaginal sheet (the favorable to the people pharmaceutical Co. Ltd in Jinan, lot number: 1108148), JIEERYIN XIYE (Sichuan En Wei pharmaceutical Co. Ltd, lot number: 1107102).
1.3 laboratory animal
Mice (SPF level) [Chengdu University of Traditional Chinese Medicine Animal Experimental Study center, production licence number: SCXK (river) 2008-11 use the quality certification number: SCXK (river) 2008-049].
1.4 culture medium, reagent and consumptive material
Sabouraud's agar (every liter contains chloromycetin 0.1g, Huankai Microbes Tech Co., Ltd., Guangdong).
Estradiol benzoate injection (Tianjin gold credit aminoacid company limited, lot number: 1007061), disposable sterilized culture dish (the healthy biological company limited in Jiangsu) etc.
1.5 key instrument
Multiple spot inoculation appearance (Japan's assistant is made institute, SAKUMA MIT-P type for a long time), laboratory is with autoclave (SANYO, MLS-3780 type), CO
2INCUBATOR (SANYO, MOC-15A), energy-saving and purifying workbench (the non-blue ultra-clean chemical industry journey company limited of the new light in Chengdu).
The experiment in vitro of experimental example 1 Fructus Tsaoko oil anti-candida albicans of the present invention
1 test method
The preparation that pastille is dull and stereotyped: adopt coubling dilution that Fructus Tsaoko oil of the present invention is diluted; Be diluted to 1:2 ~ 1:1024 totally 11 gradients respectively; In disposable sterilized culture dish, add the medicinal liquid 1ml of variable concentrations gradient and the sabouraud's agar of 14ml sterilization respectively, promptly the dilution gradient of each medicine in flat board is respectively 30.70mg/ml ~ 59.95 μ g/ml, fully mixing; The oven dry back is subsequent use, and is dull and stereotyped to add equivalent physiologic saline for substitute medication preparation positive control in dull and stereotyped.
Bacterium liquid configuration: Candida albicans type strain and clinical separation strain are transferred to bacterial concentration 1.5 * 10 with physiological saline solution
6CFU/ml.
The mensuration of minimum inhibitory concentration (MIC): adopt the pastille dull and stereotyped and positive control flat board of multiple spot inoculation appearance, and make negative control with physiologic saline for substitute bacterium liquid with the bacterium liquid adding variable concentrations gradient of experimental strain.37 ℃ of constant temperature culture 24h ~ 48h observe the growing state of each bacterial strain in containing variable concentrations gradient medicine flat board.
The result judges: with the Cmin of no albicans growth medicine in dull and stereotyped for this reason medicine to the minimum inhibitory concentration of this bacterial strain.
2 experimental results
Adopt the agar plate doubling dilution to measure medicinal herbs fruit oil of the present invention, clotrimazole and the JIEERYIN minimum inhibitory concentration to 3 strain Candida albicans type strains and 14 strain clinical separation strains, the result sees table 1.
Table 1: Fructus Tsaoko oil of the present invention is to the oidiomycetic antibacterial activity in vitro of white
Annotate: "-" representes that the Cmax of this medicine in flat board do not have obvious antibacterial activity to the Candida albicans of correspondence.Wherein inventing the Cmax of medicine in flat board is 30.70mg/ml; The Cmax of clotrimazole in flat board is 1.67mg/ml; JIEERYIN is that former medicine is done 15 times of dilutions in flat board.
Can know by table 1; The positive drug clotrimazole does not have obvious antibacterial activity to Candida albicans type strain ATCC14053 and 2 strain clinical separation strains; Explain that strain has produced drug resistance to a certain degree to clotrimazole to the part Candida albicans, the Chinese medicine JIEERYIN does not have obvious antibacterial activity external to Candida albicans.And Fructus Tsaoko oil of the present invention all has stronger antibacterial activity to 3 strain Candida albicans type strains and 14 strain clinical separation strains; Minimum inhibitory concentration to 3 strain Candida albicans type strains is 0.48mg/ml, is that (meansigma methods of minimum inhibitory concentration is 0.44 ± 0.21mg/ml) to 0.12 ~ 0.96mg/ml to the minimum inhibitory concentration that comes clinical separation strain.
Description of test medicine of the present invention has obvious external bacteriostasis and sterilization effect to Candida albicans, can treat the disease that candida albicans infection causes.
The activity in vivo of the colpitis mycotica that experimental example 2 Fructus Tsaoko oil treatment Candida albicans of the present invention cause
1 experimental technique
(1) foundation of the colpitis mycotica model that causes of mice Candida albicans
Tried the bacterium activation: CICC32819 is inoculated in sabouraud's agar with the Candida albicans type strain, cultivates 48h for 37 ℃, and is subsequent use after the activation.
Model preparation: through preliminary experiment each item factor that influences modelling is optimized, confirms the colpitis mycotica method for establishing model that Candida albicans causes.In formal experiment; Choose 70 of SPF kunming mices, body weight (20 ± 2) g, wherein 60 in preceding 6 days of infection beginning; Back subcutaneous injection 1mg/ml estradiol benzoate oil preparation 0.1ml next day of every mice, and in last 1 injection back inoculation Candida albicans 1.5 * 10
7CFU/, repeated infection is 1 time behind the 24h.And 48h and 72h get vaginal secretions respectively and carry out smear for microscopic examination behind last 1 subinfection, observe mycelia and blastopore and generate situation, are inoculated in simultaneously on the sabouraud's agar flat board, observe the growing state of bacterial strain; And variations such as observation vaginal congest, redness and secretions.In the end get mouse vagina secretions with inoculating loop behind the 1 subinfection 48h and be inoculated on the sabouraud's agar flat board and cultivate 24h ~ 48h, observe the dull and stereotyped colony growth situation that goes up Candida albicans, microscopic examination mycelial growth situation.If growth has typical Candida albicans in flat board, microscopically is observed mycelia and blastopore, explains that the colpitis mycotica model mice prepares successfully.
(2) experiment is divided into groups
After treating mice modeling success; Every mice carries out vaginadouche with the 0.1ml physiological saline solution, and flushing liquor is carried out colony counting, according to mouse vagina colony counting result mice is divided into 6 groups at random; Comprise medicine Fructus Tsaoko innage of the present invention, in, low three dose groups; Positive drug clotrimazole group and JIEERYIN group, model group, 10 every group.In addition with 10 mices that do not infect Candida albicans as blank.Wherein respectively organize the situation analysis of mouse vagina infection Candida albicans and see table 2.
Table 2: each organizes the situation analysis that mouse vagina infects Candida albicans
Annotate:
AExpression relatively has extremely significantly statistical significance (P＜0.01) with blank control group.
(3) treatment of the colpitis mycotica model mice that causes of Candida albicans
Adopt medicine intravaginal administration method that the colpitis mycotica model mice that Candida albicans causes is treated, promptly adopt every day the Fructus Tsaoko oil of the present invention of high, medium and low three dosage that the infection model mice is treated respectively, every day 1 time, 20d continuously.Positive drug is used clotrimazole and JIEERYIN respectively, and model group is used normal saline.Before administration (0d) respectively; And behind 3d, 5d and the 7d administration 6h with 0.1ml physiological saline solution washing vagina; Candida albicans in the flushing liquor is carried out colony counting; The situation of change of clump count in (0d), administration 3d, administration 5d and the administration 7d mouse vagina is observed medicine killing or inhibitory action infecting mouse intravaginal Candida albicans before the statistical analysis administration.Every day, mycelia and the blastopore growing state and the growing state in the Sha Shi flat board of vaginal secretions were observed in inoculation behind administration 7d, and the situation of change of observing every day such as mouse vagina hyperemia, redness and secretions etc.Add up healing time and the cure rate of administration 14d and administration 20d respectively.On the sabouraud's agar flat board, do not see albicans growth with continuous 3d vaginal secretions, and vagina do not have secretions, do not have clinical symptoms such as obviously hyperemia, swelling and be judged to be healing, the no longer medication of healing mice.One factor analysis of variance method comparative analysis in employing SPSS 17.0 softwares is the significance of difference between the group respectively, invents each dose groups of medicine at administration front and back and different dosing temporal differences significance with pairing T check analysis.
2 experimental results
Wherein the colony counting analysis result is seen table 3, healing time and cure rate analysis in table 4.
Table 3: Fructus Tsaoko oil of the present invention is to the influence of vaginitis model mice intravaginal albicans growth
Annotate: before 0d, 3d, 5d, 7d represent administration respectively, after the administration the 3rd day, the 5th day and the 7th day.
Compare with blank control group,
﹡ ﹡P＜0.01; With comparison before the administration,
▲P＜0.05,
▲ ▲P＜0.01; Compare with 3d after the administration,
★P＜0.05.
Can know that by table 3 before the administration, compare with blank control group, model group, positive drug group and the high, medium and low dose groups intravaginal of medicine of the present invention clump count obviously increase, and have obvious statistical significance (P＜0.01); Compare the bacterium colony number average not statistically significant (P＞0.05) of positive drug group and the high, medium and low dosage of medicine of the present invention with model group.
After the administration, compare with model group, high, medium and low dose groups of medicine of the present invention and clotrimazole group intravaginal clump count obviously descend; Compare with positive group JIEERYIN, high, medium and low dose groups of medicine of the present invention and clotrimazole group intravaginal clump count obviously descend.Compare with positive group clotrimazole, high, medium and low three dose groups of medicine of the present invention have the interior anti-candida albicans activity of similar body with it, and along with the prolongation of administration time, clump count is obvious downward trend, and the state of an illness takes a turn for the better gradually.Pairing T check analysis is found; Compare with the positive drug clotrimazole; It is active that high, medium and low three dose groups of medicine of the present invention have the colpitis mycotica that anti-candida albicans causes in the similar body: along with the prolongation of administration time, clump count is obvious downward trend, and the state of an illness takes a turn for the better gradually.Analyze the forward and backward clump count situation of change of each dose groups administration, with comparison before the administration, 3d, 5d and 7d bacterium colony number average significance decline (P＜0.05) after the high dose group administration; 3d, 5d and 7d bacterium colony number average utmost point significance decline (P＜0.01) after the middle dose groups administration; 3d, 5d and 7d bacterium colony number average significance decline (P＜0.05) after the low dose group administration.Compare with 3d after the administration, the clump count significance reduces (P＜0.05) behind the high dose group administration 7d.
Above-mentioned experimental result explanation medicine Fructus Tsaoko oil of the present invention can significantly be killed Candida albicans in vivo.
Table 4: Fructus Tsaoko oil of the present invention is to the influence of vaginitis model mice cure time
Annotate: in medication 14d statistical result, the healing time of not curing mice in the 14d is designated as 15d.In medication 20d statistical result, the healing time of not curing mice in the 20d is designated as 21d.
Compare with model group,
﹡ ﹡P＜0.01.Compare with positive group,
▲P＜0.05,
▲ ▲P＜0.01.Compare with JIEERYIN,
☆ ☆P＜0.01.Compare with high dose,
★P＜0.05,
★ ★P＜0.01.
Can know by table 4:
During medication 14d, Fructus Tsaoko innage of the present invention, in, low dose group average cure time to the vaginitis model mice in 14d is respectively 6.67d, 10.10d and 10.70d, cure rate is respectively 100.00%, 80.00% and 70.00%.Compare with model group (average cure time 14.30d, cure rate are 10.00%), three dose groups healing times of Fructus Tsaoko oil of the present invention all utmost point significance reduce (P＜0.01), and cure rate significantly improves; (average cure time 5.90d) compares with the positive drug clotrimazole, and Fructus Tsaoko innage dose groups healing time of the present invention (average cure time 6.67d) does not have obvious statistical significance (P＞0.05).(average cure time 11.30d) compares with the positive drug JIEERYIN, and Fructus Tsaoko innage dose groups healing time of the present invention significantly reduces (P＜0.01), in the Fructus Tsaoko oil of the present invention, the low dose group healing time do not have significant difference.Relatively analyze in each dose groups of Fructus Tsaoko of the present invention, compare middle dosage healing time significant prolongation (P＜0.05) with high dose; Low dosage healing time utmost point significant prolongation (P＜0.01) is obvious dose-effect relationship.
During medication 20d, Fructus Tsaoko innage of the present invention, in, low dose group average cure time to the vaginitis model mice in 20d is respectively 6.67d, 10.30d and 12.00d, cure rate is respectively 100.00%, 100.00% and 90.00%.Compare (average cure time is 18.90d, and cure rate is 30.00%) with model group, three dose groups healing times of Fructus Tsaoko oil of the present invention all utmost point significance reduce (P＜0.01), and cure rate significantly improves.Compare with the positive drug clotrimazole, Fructus Tsaoko innage dose groups healing time of the present invention does not have obvious statistical significance (P＞0.05).Compare with the positive drug JIEERYIN, Fructus Tsaoko innage dose groups healing time of the present invention significantly reduces (P＜0.01), in the Fructus Tsaoko oil of the present invention, the low dose group healing time do not have significant difference.Relatively analyze in each dose groups of Fructus Tsaoko of the present invention, wherein compare with high dose, middle dosage healing time does not have obvious statistical significance, and the low dosage healing time obviously prolongs (P＜0.05), presents obvious dose-effect relationship.
Experimental result explanation Fructus Tsaoko oil of the present invention has the effect of the colpitis mycotica that the treatment Candida albicans causes, when the high dose administration, curative effect is suitable with the positive drug clotrimazole, significantly is superior to positive Chinese medicine JIEERYIN.
To sum up; Fructus Tsaoko oil can suppress the growth of Candida albicans; Can be used for treating the disease that candida albicans infection causes, especially treat the colpitis mycotica due to the Candida albicans, interior curative effect is remarkable; Can be used for treating the exploitation and the utilization of the medicine of candida albicans infection property disease, good market prospects.
Claims (11)
1. Fructus Tsaoko oil has the purposes in the medicine that suppresses or kill the Candida albicans effect in preparation.
2. purposes according to claim 1 is characterized in that: said medicine is the medicine of treatment candidiasis.
3. purposes according to claim 2 is characterized in that: said medicine is treatment dermatocandidiasis, candidiasis of the mucous membranes, internal organs candidiasis or the oidiomycotic medicine of nervus centralis.
4. according to claim 2 or 3 described purposes, it is characterized in that: said medicine is the medicine of treatment colpitis mycotica.
5. according to any described purposes of claim 1 ~ 4, it is characterized in that: described Fructus Tsaoko oil derives from the volatile oil of the mature fruit extraction of Zingiberaceae Amomum plant Fructus Tsaoko Amomum tsa-ko Crevost et Lemaire.
6. according to any described purposes of claim 1 ~ 4; It is characterized in that: described Fructus Tsaoko oil prepares through following method: get Fructus Tsaoko; Be ground into coarse powder, add the distilled water of 10 ~ 14 times of weight, soak after 1 ~ 5 hour; Adopt steam distillation to extract 2 ~ 6 hours, promptly get Fructus Tsaoko oil.
7. one kind has the pharmaceutical composition that suppresses or kill the Candida albicans effect, it is characterized in that: it is to be active component with Fructus Tsaoko oil, adds the medicament that acceptable accessories or complementary composition are prepared from.
8. pharmaceutical composition according to claim 7 is characterized in that: described Fructus Tsaoko oil prepares through following method: get Fructus Tsaoko, be ground into coarse powder; The distilled water that adds 10 ~ 14 times of weight; Soak after 1 ~ 5 hour, adopt steam distillation to extract 2 ~ 6 hours, promptly get Fructus Tsaoko oil.
9. according to claim 7 or 8 described pharmaceutical compositions, it is characterized in that: described medicament is external preparation, oral formulations or ejection preparation.
10. pharmaceutical composition according to claim 9 is characterized in that: said external preparation is lotion, liniment, gargarism or liniment.
11. pharmaceutical composition according to claim 7 is characterized in that: the content that contains Fructus Tsaoko oil in the said preparation is 0.1%～100%w/w.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102155898A CN102716407A (en) | 2012-06-27 | 2012-06-27 | Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102155898A CN102716407A (en) | 2012-06-27 | 2012-06-27 | Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102716407A true CN102716407A (en) | 2012-10-10 |
Family
ID=46942362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102155898A Pending CN102716407A (en) | 2012-06-27 | 2012-06-27 | Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716407A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096620A (en) * | 2018-01-09 | 2018-06-01 | 中国医学科学院药用植物研究所 | The purposes of tsaoko essential oil and its emulsion as air freshener and/or air bacteriostatic agent |
| CN108124922A (en) * | 2018-01-09 | 2018-06-08 | 中国医学科学院药用植物研究所 | Tsaoko essential oil and its emulsion |
| CN107525862B (en) * | 2017-08-03 | 2020-03-17 | 广西壮族自治区中医药研究院 | Quality detection method of total flavonoid extract of kohlrabi fruits |
| US11510957B2 (en) | 2016-01-26 | 2022-11-29 | Industrial Technology Research Institute | Method for treating or alleviating autoimmune-related diseases |
| JP7447141B2 (en) | 2021-06-29 | 2024-03-11 | 中国▲熱▼▲帯▼▲農▼▲業▼科学院▲熱▼▲帯▼作物品▲種▼▲資▼源研究所 | Extraction method of Souka essential oil that inhibits Candida tropicalis and Souka essential oil |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583037A (en) * | 2004-06-02 | 2005-02-23 | 车维新 | Amomum tsao-ko volatile oil preparation, its preparing method and use |
| KR20050052839A (en) * | 2003-12-01 | 2005-06-07 | 주식회사 태평양 | Skin compositions for exteral application, containing plant extracts |
| JP2010195732A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor, beautifying agent and skin care preparation for external use |
| CN102058821A (en) * | 2009-12-28 | 2011-05-18 | 成都中医药大学 | Application of tsaoko oil in preparation of medicament for treating bacterial infection diseases |
-
2012
- 2012-06-27 CN CN2012102155898A patent/CN102716407A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050052839A (en) * | 2003-12-01 | 2005-06-07 | 주식회사 태평양 | Skin compositions for exteral application, containing plant extracts |
| CN1583037A (en) * | 2004-06-02 | 2005-02-23 | 车维新 | Amomum tsao-ko volatile oil preparation, its preparing method and use |
| JP2010195732A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor, beautifying agent and skin care preparation for external use |
| CN102058821A (en) * | 2009-12-28 | 2011-05-18 | 成都中医药大学 | Application of tsaoko oil in preparation of medicament for treating bacterial infection diseases |
Non-Patent Citations (2)
| Title |
|---|
| YANG YANG, ET AL.: "Chemical composition and antimicrobial activity of the essential oil of Amomum tsao-ko", 《JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE》, vol. 88, no. 12, 1 August 2008 (2008-08-01) * |
| 熊安言: "草果挥发油的加香试验", 《中国烟草科学》, no. 3, 31 December 2003 (2003-12-31) * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510957B2 (en) | 2016-01-26 | 2022-11-29 | Industrial Technology Research Institute | Method for treating or alleviating autoimmune-related diseases |
| CN107525862B (en) * | 2017-08-03 | 2020-03-17 | 广西壮族自治区中医药研究院 | Quality detection method of total flavonoid extract of kohlrabi fruits |
| CN108096620A (en) * | 2018-01-09 | 2018-06-01 | 中国医学科学院药用植物研究所 | The purposes of tsaoko essential oil and its emulsion as air freshener and/or air bacteriostatic agent |
| CN108124922A (en) * | 2018-01-09 | 2018-06-08 | 中国医学科学院药用植物研究所 | Tsaoko essential oil and its emulsion |
| CN108124922B (en) * | 2018-01-09 | 2021-11-26 | 中国医学科学院药用植物研究所 | Amomum tsao-ko essential oil and emulsion thereof |
| JP7447141B2 (en) | 2021-06-29 | 2024-03-11 | 中国▲熱▼▲帯▼▲農▼▲業▼科学院▲熱▼▲帯▼作物品▲種▼▲資▼源研究所 | Extraction method of Souka essential oil that inhibits Candida tropicalis and Souka essential oil |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716407A (en) | Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans | |
| CN102793881B (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel | |
| CN106822092B (en) | A kind of pharmaceutical composition inhibiting infected by Aeromonas hydrophila | |
| CN103251844B (en) | For the tablet of cleaning throat and moistening larynx | |
| CN105148142A (en) | Disposable sanitary disinfectant article containing antibacterial plant extract and preparation method of disposable sanitary disinfectant article | |
| CN105017438A (en) | Divaricate velvetplant root and rhizome polysaccharide and application thereof in preparing medicine and functional food for immune adjustment and tumor resistance | |
| CN104758397A (en) | Composition for improving sleep and preparation method thereof | |
| CN107213142A (en) | The application of oxidized resveratrol or oxidized resveratrol joint antibiotic in anti-fungal infection product is prepared | |
| CN102716408B (en) | Application of tsaoko amomum fruit to preparation of medicament for treating vaginitis | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN105031553A (en) | Medicine composition for treating dog dermatomycosis and preparation method and application thereof | |
| CN106581320A (en) | Preparation method of plant extract and preparation containing plant extract and used for women | |
| CN114306526B (en) | Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer | |
| CN108785363A (en) | Application of the yellow wingceltis platymiscium perfume (or spice) material in the drug for preparing treatment microorganism infection | |
| CN107233335A (en) | Perillaldehyde is preparing the purposes in preventing and treating the medicine of vaginitis | |
| CN108403570A (en) | There are the body condensation and preparation method of improvement to pruitus caused by eczema | |
| CN103251845B (en) | For the compositions of cleaning throat and moistening larynx | |
| CN104825744A (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel | |
| CN104436164A (en) | Foot powder containing biologic peptide composition, as well as preparation thereof | |
| CN101041686A (en) | Wood frog anticancer peptide and preparation method thereof | |
| CN109248219A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment brickpox | |
| CN104083406A (en) | Compound disinfectant and preparation method thereof | |
| CN108785383A (en) | A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof | |
| CN104212723B (en) | One strain Herba Artemisiae Japonicae Nei Shengyouwei can intend dish stey and application thereof | |
| CN110025643B (en) | Compound with anticancer activity and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121010 |